FDA guidance
Anthrax: Developing Drugs for Prophylaxis of Inhalational Anthrax Guidance for Industry
FDA guidance · Final · issued May 24, 2018
Key facts
| Title | Anthrax: Developing Drugs for Prophylaxis of Inhalational Anthrax Guidance for Industry |
|---|---|
| Status | Final |
| Issue date | May 24, 2018 |
| Center | Center for Drug Evaluation and Research |
| Issuing office | Center for Drug Evaluation and Research |
| Communication type | Guidance Document |
| Regulated product | Drugs |
| Docket number | FDA-2016-D-0412 |
| Open for comment | No |
| Document on fda.gov | fda.gov |
At a glance
- None Product codes referenced
- None Recognized standards referenced
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA guidance documents
FDA guidance documents describe the agency's current thinking on regulatory topics. Drafts are issued for comment before a final version is published.
Source: U.S. Food and Drug Administration (FDA), Guidance Documents